We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Conclusion of HIT Study

8 Apr 2011 07:00

RNS Number : 5457E
Akers Biosciences, Inc.
08 April 2011
 

Embargoed: 0700hrs 8 April 2011

Akers Biosciences, Inc.

("ABI" or the "Company")

 

Conclusion of First Heparin-induced Thrombocytopenia Study

 

Akers Biosciences, Inc. (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the results of a study recently concluded at the University of Miami/Jackson Memorial Hospital, which included an analysis of ABI's PIFA Heparin/PF-4 Rapid Assay ("PIFA test"), as well as several different laboratory methods in the screening for heparin-induced thrombocytopenia ("HIT") in critically ill patients.

 

The Company is pleased to announce that not only did its PIFA test correctly identify every positive patient but, more importantly, it produced no "false negative" results, unlike the alternative ELISA test. The study concluded that ABI's unique, patented PIFA assay can serve as a quick "rule out" test for HIT, thus assisting the physician in the rapid diagnosis of the patient's potentially serious condition.

 

In the US and EU, approximately 25 million patients are exposed to Heparin annually and 1 to 5% of those patients receive a HIT diagnosis. The largest at-risk populations are patients undergoing major cardiac or orthopedic surgical procedures. It is estimated that up to 50% of cardiac surgery patients develop HIT-antibodies, while these antibodies may be detected in close to 15% of orthopedic surgery patients. Patients with HIT are at risk of developing limb- and life-threatening complications, so the timely test result provided by ABI's PIFA test, is paramount to effective, clinical decision making.

 

Daniel Kett, M.D, one of the principal investigators of the ABI-funded study, was invited to present the conclusions at the 31st International Symposium of Intensive Care and Emergency Medicine last week in Brussels. Significantly, Dr. Kett and his colleagues proposed a new algorithm in the diagnosis of HIT that uses ABI's PIFA test, which could have an impact on how HIT patients are detected and managed.

 

The Company's new point-of care testing platform for HIT antibodies, PIFA POC, was also introduced as, with the benefit of its patented integrated blood cell separator, it will further reduce the time to diagnosis to approximately 2 minutes.

 

Dr. Kett's presentation was entitled "Heparin induced thrombocytopenia in the critically ill: How to interpret anti-PF4 antibody test results".

 

Dr. Raymond Akers, Founder & Executive Chairman of ABI, commented,

 

"We are pleased to see our test used so successfully in a clinical situation, and also that the authors thought highly enough of our product to include it in their new diagnostic algorithm for HIT. When a physician encounters a life and death situation like HIT, he or she needs a product that can be entirely relied upon to provide critical information in a timely manner. This study is a validation of our product's performance. We believe that the positive experiences reported in this study are similar to those in other institutions, and have contributed to the increase in the market penetration of this product that we have observed this year."

 

Enquiries:

 

Thomas A. Nicolette, President and CEO

Dr Raymond F. Akers, Jr., Executive Chairman

Tel. +1 856 848 8698

Antony Legge or Noelle Greenaway

Daniel Stewart & Company plc (Nomad and Broker)

Tel. +44 (0)20 7776 6550

 

Ben Simons

M: Communications

Tel. +44 (0)20 7920 2340

 

About Akers Biosciences, Inc.

 

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical product distributors to maximise product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCIRMLTMBJMBMB
Date   Source Headline
31st Dec 20157:00 amRNSIssue of Equity & Directors' Shareholdings
1st Dec 20157:00 amRNSAkers Biosciences Updates on JV in China
23rd Nov 20157:00 amRNSAppointment of CEO
13th Nov 20157:00 amRNS3rd Quarter Results
12th Nov 201512:00 pmRNSAppointment of Non-Executive Director
11th Nov 20157:00 amRNSNotice of Q3 Results
4th Nov 20157:00 amRNSHIT Test Approved by Chinese FDA
6th Oct 20157:00 amRNSCommercialization of New Breath Tests
30th Sep 20157:00 amRNSDistribution Agreements
14th Sep 20157:00 amRNSLaunch of Breath Ketone test
18th Aug 20157:00 amRNSHalf Yearly Report
14th Aug 20157:00 amRNSNotice of Half Yearly Results
13th Aug 20157:00 amRNSNotice of Half Yearly Results
3rd Aug 20155:29 pmRNSResult of AGM
30th Jun 20152:00 pmRNSAppointment of Non-Executive Director
25th Jun 20155:00 pmRNSAdjournment of Annual General Meeting
16th Jun 20152:30 pmRNSUpdate on Rapid Breath Tests for Wellness Industry
5th Jun 20153:45 pmRNSNotice of AGM and Proposed Board Changes
14th May 20157:00 amRNS1st Quarter Results
12th May 20157:20 amRNSAkers Introduces New Rapid Breath Tests
11th May 20155:50 pmRNSNotice of Q1 Results
11th May 20157:00 amRNSClaim Against ChubeWorkx Guernsey Limited
6th May 20157:01 amRNSResale Agreement
13th Apr 20157:00 amRNSDistribution Agreements
2nd Apr 20157:00 amRNSDistribution Agreement
23rd Mar 201510:52 amRNSFinal Results
19th Mar 20157:00 amRNSNotice of Results
9th Feb 201512:00 pmRNSAkers' Management System Certified to ISO 13485
26th Jan 20157:00 amRNSEuropean Patent Granted
20th Jan 20157:00 amRNSExpansion of US Sales Effort with Key Appointments
9th Jan 20153:03 pmRNSIssue of Equity
9th Jan 20157:00 amRNSIncentive Stock and Award Plan
18th Dec 20147:00 amRNSEuropean Distribution Agreements
10th Dec 20147:00 amRNSOrder to Supply PIFA Products to China
13th Nov 201412:00 pmRNSThird Quarter Results
10th Nov 201412:00 pmRNSNotice of Third Quarter Results
4th Nov 20144:49 pmRNSResult of AGM
23rd Oct 20141:20 pmRNSJV to Market Rapid Diagnostic Tests in China
17th Oct 20143:10 pmRNSNotice of AGM
16th Sep 20145:53 pmRNSAKERS BIOSCIENCES FEATURES ON GLOBAL MEDIA
9th Sep 201412:30 pmRNSSALES CONTRACT FOR RAPID CHOLESTEROL TEST
8th Sep 20147:00 amRNSChange of Adviser
15th Aug 20147:00 amRNSAppointment of Co-chairman
12th Aug 201411:00 amRNSHalf Yearly Report
5th Aug 20147:00 amRNSSenior Managerial Appointment
28th Jul 20147:00 amRNSFeasibility Study For Heart Attack Test
17th Jul 20147:00 amRNSUS Patent - Breath Ketone Detection Device
30th Jun 20147:00 amRNSPosting of Annual Report and Accounts
25th Jun 20147:00 amRNSUS Distribution Agreement
13th Jun 201411:11 amRNSGrant of Options and Directors Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.